AU2001271066A1 - Method for screening ligand having biological activity - Google Patents
Method for screening ligand having biological activityInfo
- Publication number
- AU2001271066A1 AU2001271066A1 AU2001271066A AU7106601A AU2001271066A1 AU 2001271066 A1 AU2001271066 A1 AU 2001271066A1 AU 2001271066 A AU2001271066 A AU 2001271066A AU 7106601 A AU7106601 A AU 7106601A AU 2001271066 A1 AU2001271066 A1 AU 2001271066A1
- Authority
- AU
- Australia
- Prior art keywords
- biological activity
- screening ligand
- ligand
- screening
- biological
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000004071 biological effect Effects 0.000 title 1
- 239000003446 ligand Substances 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 238000012216 screening Methods 0.000 title 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Obesity (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Transplantation (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000-221070 | 2000-07-17 | ||
JP2000221070 | 2000-07-17 | ||
JP2001159032 | 2001-05-28 | ||
JP2001-159032 | 2001-05-28 | ||
PCT/JP2001/006170 WO2002006838A1 (en) | 2000-07-17 | 2001-07-17 | Method for screening ligand having biological activity |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2001271066A1 true AU2001271066A1 (en) | 2002-01-30 |
Family
ID=26596454
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2001271066A Abandoned AU2001271066A1 (en) | 2000-07-17 | 2001-07-17 | Method for screening ligand having biological activity |
Country Status (5)
Country | Link |
---|---|
US (1) | US7732133B2 (en) |
EP (1) | EP1304573A4 (en) |
JP (1) | JP4908721B2 (en) |
AU (1) | AU2001271066A1 (en) |
WO (1) | WO2002006838A1 (en) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006180705A (en) * | 2003-03-06 | 2006-07-13 | Chugai Pharmaceut Co Ltd | Chimeric receptor and method for screening ligand or inhibitor for the receptor |
WO2005035754A1 (en) | 2003-10-14 | 2005-04-21 | Chugai Seiyaku Kabushiki Kaisha | Double specific antibodies substituting for functional protein |
EP2286838A3 (en) | 2004-11-01 | 2013-09-04 | Amylin Pharmaceuticals, LLC | Treatment of obesity and related disorders |
WO2006106905A1 (en) | 2005-03-31 | 2006-10-12 | Chugai Seiyaku Kabushiki Kaisha | Process for production of polypeptide by regulation of assembly |
US20110038854A1 (en) * | 2006-03-30 | 2011-02-17 | University Of Medicine And Dentistry Of New Jersey | Strategy for homo- or hetero-dimerization of various proteins in solution and in cell |
DK2009101T3 (en) | 2006-03-31 | 2018-01-15 | Chugai Pharmaceutical Co Ltd | Antibody modification method for purification of a bispecific antibody |
US11046784B2 (en) | 2006-03-31 | 2021-06-29 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
JP2008102117A (en) | 2006-09-21 | 2008-05-01 | Fujifilm Corp | Surface plasmon enhanced fluorescence sensor and fluorescence detecting method |
SI2202245T1 (en) | 2007-09-26 | 2016-10-28 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substitution in cdr |
CN105859889B (en) | 2010-11-17 | 2020-01-07 | 中外制药株式会社 | Multispecific antigen-binding molecules having a function replacing the function of factor VIII |
BR112016006197B1 (en) | 2013-09-27 | 2023-04-11 | Chugai Seiyaku Kabushiki Kaisha | METHOD FOR PRODUCING A BISPECIFIC POLYPEPTIDE ANTIBODY |
TWI700300B (en) | 2014-09-26 | 2020-08-01 | 日商中外製藥股份有限公司 | Antibodies that neutralize substances with the function of FVIII coagulation factor (FVIII) |
TWI701435B (en) | 2014-09-26 | 2020-08-11 | 日商中外製藥股份有限公司 | Method to determine the reactivity of FVIII |
WO2016159213A1 (en) | 2015-04-01 | 2016-10-06 | 中外製薬株式会社 | Method for producing polypeptide hetero-oligomer |
GB201522097D0 (en) * | 2015-12-15 | 2016-01-27 | Cellular Therapeutics Ltd | Cells |
EP3398965A4 (en) | 2015-12-28 | 2019-09-18 | Chugai Seiyaku Kabushiki Kaisha | Method for promoting efficiency of purification of fc region-containing polypeptide |
EP3509637A4 (en) | 2016-09-06 | 2020-05-27 | Chugai Seiyaku Kabushiki Kaisha | Methods of using a bispecific antibody that recognizes coagulation factor ix and/or activated coagulation factor ix and coagulation factor x and/or activated coagulation factor x |
KR20240059648A (en) | 2017-04-19 | 2024-05-07 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | Immune cells expressing engineered antigen receptors |
CA3071236A1 (en) | 2017-09-29 | 2019-04-04 | Chugai Seiyaku Kabushiki Kaisha | Multispecific antigen-binding molecule having blood coagulation factor viii (fviii) cofactor function-substituting activity, and pharmaceutical formulation containing said molecule as active ingredient |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3514272A1 (en) * | 1985-04-17 | 1986-10-23 | Schering AG, 1000 Berlin und 4709 Bergkamen | DERMATICA |
US4859609A (en) | 1986-04-30 | 1989-08-22 | Genentech, Inc. | Novel receptors for efficient determination of ligands and their antagonists or agonists |
DK0521156T4 (en) * | 1990-03-23 | 2008-01-07 | Osaka Bioscience Inst | DNA encoding granulocyte colony-stimulating factor receptor |
EP1281702B1 (en) | 1991-08-23 | 2005-12-21 | Nps Pharmaceuticals, Inc. | Calcium receptor active molecules |
JPH08508889A (en) | 1993-06-07 | 1996-09-24 | アムジエン・インコーポレーテツド | Hybrid receptor molecule |
EP0830600B1 (en) | 1995-06-07 | 2003-08-27 | Praecis Pharmaceuticals Incorporated | Functional bioassay for g-protein coupled receptor agonists and antagonists |
US5866341A (en) * | 1996-04-03 | 1999-02-02 | Chugai Pharmaceutical Co., Ltd. | Compositions and methods for screening drug libraries |
WO2001025797A2 (en) * | 1999-10-06 | 2001-04-12 | Sumitomo Chemical Company, Limited | Methods of evaluating whether a test agent is an agent affecting a leptin receptor |
-
2001
- 2001-07-17 AU AU2001271066A patent/AU2001271066A1/en not_active Abandoned
- 2001-07-17 EP EP01950013A patent/EP1304573A4/en not_active Ceased
- 2001-07-17 WO PCT/JP2001/006170 patent/WO2002006838A1/en active Application Filing
- 2001-07-17 US US10/333,103 patent/US7732133B2/en not_active Expired - Fee Related
- 2001-07-17 JP JP2002512695A patent/JP4908721B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
WO2002006838A1 (en) | 2002-01-24 |
EP1304573A4 (en) | 2006-06-07 |
US20040091876A1 (en) | 2004-05-13 |
JP4908721B2 (en) | 2012-04-04 |
US7732133B2 (en) | 2010-06-08 |
EP1304573A1 (en) | 2003-04-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2001271066A1 (en) | Method for screening ligand having biological activity | |
EP1469316A2 (en) | Screening method | |
EP1113094A3 (en) | Plating analysis method | |
MXPA01010625A (en) | Method for down-regulating il5 activity. | |
HUP0402231A3 (en) | A method for determining the biological activity defibrotide | |
AU7433900A (en) | Screening methods | |
AU2001267978A1 (en) | Method for analyzing words | |
AU2308900A (en) | Analysis method | |
AU4051800A (en) | Method for preparing and screening catalysts | |
AU2002237261A1 (en) | Rapid method for screening compounds for in vivo activity | |
AU1553101A (en) | Screening method | |
IL137371A0 (en) | Gene expression methods for screening compounds | |
GB9923075D0 (en) | Screening method | |
AU2001230365A1 (en) | Method of screening compounds for biological activity | |
AU6429000A (en) | Screening method | |
AU2001268514A1 (en) | Method for screening dna binding | |
AU2002247215A1 (en) | Method for screening compounds | |
AU2001283111A1 (en) | Electrolytic system and methods for screening catalytic material | |
AU5039200A (en) | Reciprocating biological filter | |
AU2002258787A1 (en) | Screening methods for identifying ligands | |
AU2872501A (en) | Screening method | |
AU2001261259A1 (en) | Diagnostic method for screening complement regulatory protein levels | |
AU4856501A (en) | Screening method for compounds | |
AU1704000A (en) | Method for diagnostic screening | |
GB9930255D0 (en) | Screening method |